Enzyme News and Research

RSS

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

Scientists discover key molecular mechanism in breast cancer metastasis

Scientists at the University of Kentucky Markey Cancer Center have identified a key molecular mechanism in breast cancer that enables tumor cells to spread to adjacent or distant parts of the body in a process called metastasis.

5 May 2010

Cambrex first-quarter sales down 6.4% to $56.2 million

Cambrex Corporation reports first quarter results for the period ended March 31, 2010.

4 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Children with ADHD who carry a specific type of dopamine receptor gene respond better to the drug methylphenidate than those without the genotype, according to new research from Cincinnati Children's Hospital Medical Center.

4 May 2010

Natural plant extract could help treat COPD and inflammatory disorders

A widely and safely used plant extract acts as a novel anti-inflammatory agent that may one day be used for the treatment of chronic obstructive pulmonary disease, or COPD, as well as other inflammatory conditions.

4 May 2010

ZENPEP CF Cycle for Life to be launched to support research and cure for cystic fibrosis

Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP CF Cycle for Life, begins in San Francisco on June 26.

4 May 2010

Neural stem cell transplantation promising for Batten disease

Neuronal Ceroid Liposfuscinosis (NCL), often referred to as Batten disease, is a rare and fatal neurodegenerative disorder that afflicts infants and young children. NCL is caused by a deficiency of a lysosomal enzyme, and is a relatively rare disease, affecting an estimated 2 to 4 of every 100,000 babies born in the U.S. Although NCLs are classified as rare diseases, they often affect more than one child in families that carry the defective gene, and tragically, are always fatal.

4 May 2010

Early or delayed puberty can trigger antisocial behavior in adolescent boys

Puberty that arrives earlier or later in adolescent boys relative to their peers can trigger chemicals that are related to antisocial behavior, according to researchers, whose findings have key implications for parents with aggressive boys.

4 May 2010

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.

4 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

CAM use higher among children with GI symptoms: Study

Complementary and alternative medicine is becoming a popular treatment for a variety of conditions, with national data showing it is used by about 12 percent of children.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

According to the Alzheimer's Association, over 5 million Americans are afflicted with Alzheimer's disease. While its cause is controversial, many people believe a correlation exists with toxin accumulation. Until recently, chelation, an invasive, drug-based toxin removal therapy, has been patients' primary option.

30 Apr 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Eliminating inherent drug resistance in tuberculosis

Tuberculosis (TB) continues to be a global health problem, in part due to the exceptional drug resistance displayed by the TB-causing agent, Mycobacterium tuberculosis. Beyond even acquired drug resistance, these bacteria are also inherently resistant to many other common antibiotics, which limits the available options in finding alternative treatments to resistant TB strains.

29 Apr 2010

Enzyme News and Research

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Scientists discover key molecular mechanism in breast cancer metastasis

Cambrex first-quarter sales down 6.4% to $56.2 million

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Research makes progress in ending guesswork involved in prescribing effective ADHD medications

Natural plant extract could help treat COPD and inflammatory disorders

ZENPEP CF Cycle for Life to be launched to support research and cure for cystic fibrosis

Neural stem cell transplantation promising for Batten disease

Early or delayed puberty can trigger antisocial behavior in adolescent boys

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

CAM use higher among children with GI symptoms: Study

Vitamin E effective in treating NASH: Study

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

New PCA-Rx therapy provides natural toxin removal treatment to Alzheimer's patients

NWO awards 31 grants in Investment Subsidy NWO Medium programme

Eliminating inherent drug resistance in tuberculosis

Biochemistry eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News